Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Share News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Crest Nicholson Woes Topple Housebuilders

Tue, 12th Jun 2018 10:52

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Centrica, up 2.1%. Jefferies raised the energy services company to a Buy rating from Hold and also increased its target price to 165 pence from 140p.----------Reckitt Benckiser, up 1.6%. Credit Suisse upped the health and hygiene products manufacturer to 5,500 pence from 5,450p, retaining its Underperform rating.----------FTSE 100 - LOSERS----------Barratt Developments, down 2.2%, Berkeley Group Holdings, down 2.1%, Persimmon, down 1.4% and Taylor Wimpey, down 1.4%. Blue chip housebuilders fell to the bottom of the index after FTSE 250-listed Crest Nicholson reported drop in first half margins and warned annual margins will be at the bottom end of its guidance range.----------FTSE 250 - WINNERS----------IMI, up 2.5%. Morgan Stanley upped the engineering firm to an Overweight rating from Equal Weight, and raised its price target to 1,410 pence from 1,180p.----------Greencore Group, up 0.8%. Numis raised the sandwich maker to an Add rating from Hold, along with the price target to 210 pence from 138p.----------Fidelity China Special Situations, up 1.2%. Although the China-focused investment trust had a net asset value total return of 22.2%, underperforming the MSCI China Index which returned 23.6% for the year to the end of March, Fidelity reported a substantial rise in net asset value per share at 272.55 pence as at March 31, up from 225.36p on the same date the year before. In addition, the trust declared a final dividend of 3.50 pence, up 40% from 2.50p the year before.----------FTSE 250 - LOSERS----------Crest Nicholson Holdings, down 5.9%. The housebuilder reported a 2% drop in pretax profit for the six months ended April 30 to GBP74.8 million from GBP76.2 million year-on-year. Headline gross margins for the period were at 23.6%, down from 26.3% the prior year due to flat pricing amid a backdrop of build cost inflation at 3% to 4%. Crest Nicholson said it expects operating margins for the full year at around 18%, lower compared to last year at 20.3%. This is at the bottom range of Crest Nicholson's guidance range of 18% to 20%.----------Domino's Pizza Group, down 5.5%. The pizza retailer reported the resignation of Chief Financial Officer and board member Rachel Osborne and said that it has commenced a search for her successor. Osborne's resignation was effective from Monday and the company did not give any specific details regarding her departure. The pizza retailer also reiterated its earnings outlook given in March and remains confidence regarding its performance in 2018 and beyond.----------Ted Baker, down 3.6%. The lifestyle group for the 19-week period from January 28 to June 9 reported revenue increase by 4.2% compared with the same period a year ago. "This performance was achieved despite the impact of unseasonal weather across Europe and the East Coast of America in the early part of the period and, as previously reported, external trading conditions remaining challenging across many of our global markets," the company said. Total retail sales for the period increased by 0.7%, with e-commerce sales up 34%.----------OTHER MAIN MARKET AND AIM - WINNERS----------Clear Leisure, up 11%. The leisure sector investment company reached a settlement agreement with Peter McBride regarding an interest on a loan the company owed him. The settlement is in regard to an amount of GBP91,722 relating to interest accrued on a loan of GBP250,000 made by Square One Ltd to Clear Leisure in March 2015. Settlement will be reached through the issue and allotment of 8.3 million shares at 1.11 pence each. Square One assigned the benefit of the interest to McBride in February.----------OTHER MAIN MARKET AND AIM - LOSERS----------Stratex International, down 16%. The gold exploration company said it entered a conditional option agreement with Bureau d'Etudes et d'Investigations Geologico-minieres, Geotechniques et Geophysiques SARL, for its two early stage projects Bibemi and Wapouze in north Cameroon. Stratex will manage the project, while Bureau provides consulting and operational support. In addition, to support the placing, Stratex intends to raise GBP1 million through a placing of shares at the expected price of 0.5 pence per share. ----------IXICO, down 10%. The clinical trial data management services provider announced the cessation of a trial of an Alzheimer's disease treatment. IXICO didn't state whether or not the treatment in question was AstraZeneca's lanabecestat, for which the phase three trials have been discontinued. IXICO was providing specialist imaging clinical trial services for the trial. The USD7.7 million contract for the clinical trial was secured in September 2017 by IXICO and was scheduled to end in 2024. Over the past three years, IXICO recognised USD2.0 million from the contract. The termination of the trial is not expected to materially impact the company's performance and IXICO remains on track to generating revenue in excess of GBP4.5 million and meet market expectations for the current financial year.----------
More News
7 Dec 2021 15:41

Ixico sees "significant growth" despite notable headwinds; shares up

Ixico sees "significant growth" despite notable headwinds; shares up

Read more
30 Nov 2021 16:26

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
1 Nov 2021 15:43

Ixico tapped for another phase-3 clinical trial

(Sharecast News) - Artificial intelligence (AI) data analytics company Ixico has been selected by its largest pharmaceutical client to provide neuroimaging services for a new phase 3 clinical trial focussed on a demyelinating disorder, it announced on Monday.

Read more
18 Oct 2021 09:33

Ixico FY revenues projected to beat expectations

(Sharecast News) - AI data analytics company Ixico said on Monday that full-year revenues were projected to have beat expectations despite falling shy of prior year comparatives.

Read more
22 Sep 2021 11:19

Ixico secures new contract valued at more than $750,000

(Sharecast News) - AI data analytics firm Ixico has secured a new contract valued at more than $750,000 over two years for advanced neuroimaging solutions.

Read more
8 Sep 2021 12:47

Ixico awarded phase 1 clinical trial contract

(Sharecast News) - Neuroscience artificial intelligence (AI) company Ixico has been awarded a contract by a new biopharmaceutical client to support its phase 1 multiple system atrophy clinical trial, it announced on Wednesday.

Read more
6 Aug 2021 14:53

Ixico confident as full-year revenue, earnings decline

(Sharecast News) - Data analytics company Ixico updated the market on its trading on Friday, confirming that despite a "challenging" business environment, it expected to deliver £8.7m in revenues for the 2021 financial year.

Read more
26 Apr 2021 09:06

Ixico H1 revenues grow despite Covid-19 impacts on clinical development sector

(Sharecast News) - Clinical research firm Ixico said on Monday that revenues were expected to have improved in the six months ended 31 March, despite the impacts of the Covid-19 pandemic on the clinical development sector.

Read more
15 Mar 2021 10:13

Ixico strikes collaboration deal with Microsoft

(Sharecast News) - Data analytics company Ixico said on Monday that it had struck a collaboration agreement with tech giant Microsoft to develop its artificial intelligence analytics platform for the global pharmaceutical industry.

Read more
10 Mar 2021 14:30

Ixico selected for Alzheimer's clinical trial

(Sharecast News) - Neuroscience artificial intelligence (AI) analytics company Ixico has been selected by a current mid-sized biopharmaceutical client to support a phase 2 Alzheimer's disease clinical trial, it announced on Wednesday.

Read more
24 Dec 2020 12:20

Ixico awarded ?3.4m contract by existing client

(Sharecast News) - Artificial intelligence (AI) data analytics company Ixico has been awarded a £3.4m contract to run over 4.5 years by an existing client, it announced on Thursday, for a spinocerebellar ataxia type-3 (SCA3) trial.

Read more
8 Dec 2020 09:26

Ixico to provide neuroimaging solutions to unnamed global pharmaceutical group

(Sharecast News) - Data analytics firm Ixico has secured a contract for neuroimaging solutions with a "large global pharmaceutical company".

Read more
27 Nov 2020 12:09

Ixico executes contract for Huntington's disease clinical trial

(Sharecast News) - Neuroscience data analytics company Ixico has executed a contract to provide neuroimaging services that would support a phase 1b and 2 clinical trial for Huntington's disease, it announced on Friday.

Read more
3 Nov 2020 10:43

Ixico wins new contracts in Alzheimer's clinical trials

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Alzheimer's disease (AD) clinical trials, it announced on Tuesday.

Read more
22 Oct 2020 15:00

Ixico secures two Huntington's disease clinical trial contracts

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Huntington's disease clinical trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.